Caxton Associates (New York)’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Caxton Associates (New York)’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,524	Closed	-$685K	–	800
2022 Q1	$685K	Buy	25,524 +9,836	+63%	+$331K	0.06%	172
2021 Q4	$748K	Buy	+15,688	New	+$701K	0.08%	174
2021 Q3	–	Sell	-4,931	Closed	-$385K	–	643
2021 Q2	$385K	Buy	+4,931	New	+$364K	0.04%	243

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Caxton Associates (New York)'s TPTX Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 25,524 shares — an estimated $685K sold.

Caxton Associates (New York) first reported a position in TPTX in Q2 2021 and held it in 3 quarters. The position peaked at $748K in Q4 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Caxton Associates (New York) reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Caxton Associates (New York) sold 25,524 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $685K.
Caxton Associates (New York) first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
Caxton Associates (New York)'s Turning Point Therapeutics, Inc. Common Stock position peaked at $748K in Q4 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.